STOCK TITAN

Pieris Pharmaceuticals to Host Second Quarter 2022 Investor Call and Provide Corporate Update on August 4, 2022

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Pieris Pharmaceuticals (NASDAQ:PIRS) will host a second quarter 2022 investor call on August 4, 2022, at 8:00 AM EDT. The call will cover financial results and provide a corporate update. Participants can join by dialing (800) 285-6670 for US & Canada or (713) 481-1320 internationally, at least five minutes prior. A listen-only audio webcast will also be available. A replay will be posted on the company’s website for those unable to attend. For more information, visit pieris.com.

Positive
  • None.
Negative
  • None.

BOSTON, MA / ACCESSWIRE / July 28, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a second quarter 2022 investor call on Thursday, August 4, 2022 at 8:00 AM EDT to discuss financial results and provide a corporate update.

To access the call, participants may dial (800) 285-6670 (Toll Free US & Canada) or (713) 481-1320 (International) at least five minutes prior to the start of the call. Alternatively, a listen-only audio webcast of the call can be accessed here.

For those unable to participate in the conference call or listen to the webcast, a replay will be available on the Investors section of the Company's website, www.pieris.com.

About Pieris Pharmaceuticals:

Pieris is a clinical-stage biotechnology company that combines leading protein engineering capabilities and deep understanding into molecular drivers of disease to develop medicines that drive local biology to produce superior clinical outcomes for patients. Our pipeline includes inhalable Anticalin proteins to treat respiratory diseases and locally-activated bispecifics for immuno-oncology. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by respiratory and immuno-oncology focused partnerships with leading pharmaceutical companies. For more information, visit www.pieris.com.

Investor Relations Contact:

Pieris Pharmaceuticals, Inc.
Maria Kelman
Executive Director, Investor Relations
+1 857 362 9635
kelman@pieris.com

SOURCE: Pieris Pharmaceuticals, Inc.



View source version on accesswire.com:
https://www.accesswire.com/710100/Pieris-Pharmaceuticals-to-Host-Second-Quarter-2022-Investor-Call-and-Provide-Corporate-Update-on-August-4-2022

FAQ

What is the date of the investor call for Pieris Pharmaceuticals?

The investor call for Pieris Pharmaceuticals is scheduled for August 4, 2022.

How can I access the Pieris Pharmaceuticals investor call?

You can access the Pieris Pharmaceuticals investor call by dialing (800) 285-6670 in the US or (713) 481-1320 internationally, or by listening to the audio webcast available on their website.

What time is the Pieris Pharmaceuticals investor call?

The Pieris Pharmaceuticals investor call will take place at 8:00 AM EDT.

Where can I find the replay of the Pieris Pharmaceuticals investor call?

The replay of the Pieris Pharmaceuticals investor call will be available on the Investors section of their website.

What will be discussed during the Pieris Pharmaceuticals investor call?

The investor call will discuss financial results and provide a corporate update.

PIERIS PHARMACEUTICALS INC

NASDAQ:PIRS

PIRS Rankings

PIRS Latest News

PIRS Stock Data

17.96M
1.30M
0.07%
52.92%
1.7%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BOSTON